Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.38 |
| ▸ | MEN1 | O00255 | 7/20 | 0.38 |
| ▸ | APP | P05067 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21800623 | 0.88 | APP (0.37) | KMT2AMEN1APPALDH1A1LMNA | |
| SCHEMBL17162743 | 0.81 | OPRM1 (0.34) | KMT2AMEN1APPALDH1A1MAPT | |
| SCHEMBL1310474 | 0.77 | MEN1 (0.45) | KMT2AMEN1ALDH1A1MAPTPOLB | |
| SCHEMBL21749202 | 0.77 | L3MBTL1 (0.41) | KMT2AMEN1ALDH1A1POLBRAB9A | |
| SCHEMBL26115458 | 0.76 | KDM1A (0.30) | — | |
| SCHEMBL1764700 | 0.76 | CYP4F2 (0.49) | KMT2AMEN1RAB9AGAA | |
| SCHEMBL4556747 | 0.75 | MEN1 (0.43) | KMT2AMEN1ALDH1A1MAPTPOLB | |
| SCHEMBL1447297 | 0.73 | KMT2A (0.46) | KMT2AMEN1ALDH1A1MAPTPOLB | |
| SCHEMBL22981673 | 0.73 | KMT2A (0.52) | KMT2AMEN1POLBRAB9AGAA | |
| SCHEMBL17611774 | 0.72 | MEN1 (0.42) | KMT2AMEN1ALDH1A1MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11203600-B2 | Kinase inhibitors and uses thereof | DENALI THERAPEUTICS INC. (US) | 2021-12-21 | — | — | US | disclosed |
| EP-3624797-A1 | KINASE INHIBITORS AND USES THEREOF | Denali Therapeutics Inc. (US) | 2020-03-25 | — | — | EP | disclosed |
| US-20200087319-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2020-03-19 | — | — | US | disclosed |
| WO-2018213632-A1 | KINASE INHIBITORS AND USES THEREOF | DENALI THERAPEUTICS INC. (US) | 2018-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087319-A1 | Kinase Inhibitors and Uses Thereof | MAP3K20, MAP3K6, MAP3K19 | KMT2A 1686/4885MEN1 2281/4885APP 4450/4885 |
| US-11203600-B2 | Kinase inhibitors and uses thereof | MAP3K20, MAP3K6, MAP3K19 | KMT2A 1686/4885MEN1 2281/4885APP 4450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.